Articles related to ALZHEIMER'S DISEASE (AD)
Flavonols Linked to Slower Cognitive Decline
Prior research showed that higher flavonol consumption was associated with lower Alzheimer’s risk. This longitudinal study demonstrated that increased flavonol consumption yielded slower declines in global cognition and in episodic, semantic, and working memory, independent of other health and lifestyle factors.
Clinical Pharmacology November 29th 2022
Gantenerumab Did Not Slow Clinical Decline as Expected in Individuals with Early Alzheimer Disease
Gantenerumab treatment generated a slowing of clinical decline from baseline score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), but at levels that did not reach statistical significance. The relative reduction in clinical decline was 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.
Neurology November 29th 2022
Dementia Signs Emerge Up to 9 Years Before Diagnoses
The findings point to the possibility of very early detection of dementias, when recruitment into preventive trials, drug trials, and implementation of preventive strategies to slow the disease have the most impact.
Neurology October 25th 2022
Study Confirms Benefits of Lecanemab in Early Alzheimer Disease
In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.
Neurology October 7th 2022
ALZ-801 Trial Results Announced: A Breakthrough in Alzheimer’s Treatment?
On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.
Internal Medicine September 26th 2022
Association of Amyloid Reduction After Donanemab Treatment with Tau Pathology and Clinical Outcomes
The TRAILBLAZER-ALZ Randomized Clinical Trial According to the findings of post-hoc analysis for patients who received donanemab treatment, baseline amyloid levels were directly related to the extent of amyloid reduction and inversely related to the likelihood of obtaining total amyloid clearance. In patients with complete amyloid clearance and in brain areas discovered later in the pathologic sequence, the donanemab-induced slowing of tau was more severe. To support the aforementioned findings, data from additional trials would be crucial, particularly information on treatment response according to APOE ε4 status.
Neurology September 19th 2022